SI20026B - Heptapeptidni analogi - antagonisti oksitocina - Google Patents

Heptapeptidni analogi - antagonisti oksitocina Download PDF

Info

Publication number
SI20026B
SI20026B SI9720076A SI9720076A SI20026B SI 20026 B SI20026 B SI 20026B SI 9720076 A SI9720076 A SI 9720076A SI 9720076 A SI9720076 A SI 9720076A SI 20026 B SI20026 B SI 20026B
Authority
SI
Slovenia
Prior art keywords
abu
asn
ile
mpa
ch2oh
Prior art date
Application number
SI9720076A
Other languages
English (en)
Slovenian (sl)
Other versions
SI20026A (sl
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI20026A publication Critical patent/SI20026A/sl
Publication of SI20026B publication Critical patent/SI20026B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI9720076A 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina SI20026B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
SI20026A SI20026A (sl) 2000-02-29
SI20026B true SI20026B (sl) 2000-06-30

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720076A SI20026B (sl) 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina

Country Status (35)

Country Link
US (1) US6143722A (ko)
EP (1) EP0938496B1 (ko)
JP (1) JP3405460B2 (ko)
KR (1) KR100463132B1 (ko)
CN (1) CN1129606C (ko)
AR (1) AR008531A1 (ko)
AT (1) ATE242264T1 (ko)
AU (1) AU713424B2 (ko)
BR (1) BR9713366B1 (ko)
CA (1) CA2272990C (ko)
CZ (1) CZ299532B6 (ko)
DE (1) DE69722651T2 (ko)
DK (1) DK0938496T3 (ko)
EE (1) EE03832B1 (ko)
ES (1) ES2203823T3 (ko)
HK (1) HK1022481A1 (ko)
HR (1) HRP970630B1 (ko)
HU (1) HU228568B1 (ko)
IL (1) IL129519A (ko)
LT (1) LT4650B (ko)
LV (1) LV12350B (ko)
MY (1) MY125555A (ko)
NO (1) NO321380B1 (ko)
NZ (1) NZ336445A (ko)
PL (1) PL189292B1 (ko)
PT (1) PT938496E (ko)
RO (1) RO120772B1 (ko)
RU (1) RU2180668C2 (ko)
SE (1) SE9604341D0 (ko)
SI (1) SI20026B (ko)
SK (1) SK283800B6 (ko)
TR (1) TR199901028T2 (ko)
UA (1) UA54459C2 (ko)
WO (1) WO1998023636A1 (ko)
ZA (1) ZA9710518B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
EP1480998B1 (en) * 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
AU2003229735A1 (en) * 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
DK1530967T3 (da) * 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
AU2009233429B2 (en) * 2008-03-31 2014-02-13 Ferring B.V. Oxytocin analogues
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP2712622B1 (en) 2008-05-21 2016-07-13 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
SG187038A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2012121057A1 (ja) 2011-03-09 2012-09-13 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108290929A (zh) 2015-10-06 2018-07-17 辉凌公司 制造巴芦西班及其中间体的新型方法
AU2017205670B2 (en) 2016-01-04 2021-05-20 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
BR9713366B1 (pt) 2010-05-18
RU2180668C2 (ru) 2002-03-20
TR199901028T2 (xx) 1999-07-21
US6143722A (en) 2000-11-07
CZ299532B6 (cs) 2008-08-27
HRP970630A2 (en) 1998-10-31
ZA9710518B (en) 1998-06-10
JP3405460B2 (ja) 2003-05-12
HK1022481A1 (en) 2000-08-11
CN1238781A (zh) 1999-12-15
NO992532L (no) 1999-05-26
SK70499A3 (en) 2000-10-09
EE9900210A (et) 1999-12-15
WO1998023636A1 (en) 1998-06-04
NZ336445A (en) 2000-06-23
LT99052A (en) 2000-01-25
LV12350A (lv) 1999-09-20
NO321380B1 (no) 2006-05-02
KR100463132B1 (ko) 2004-12-23
PL189292B1 (pl) 2005-07-29
ES2203823T3 (es) 2004-04-16
EP0938496A1 (en) 1999-09-01
AU5142998A (en) 1998-06-22
DK0938496T3 (da) 2003-10-06
LT4650B (lt) 2000-04-25
HUP0000577A3 (en) 2001-02-28
CA2272990A1 (en) 1998-06-04
BR9713366A (pt) 2000-01-25
LV12350B (en) 1999-11-20
HU228568B1 (en) 2013-04-29
NO992532D0 (no) 1999-05-26
HRP970630B1 (en) 2002-04-30
EE03832B1 (et) 2002-08-15
ATE242264T1 (de) 2003-06-15
IL129519A (en) 2004-09-27
RO120772B1 (ro) 2006-07-28
AR008531A1 (es) 2000-01-19
PT938496E (pt) 2003-10-31
HUP0000577A2 (hu) 2000-11-28
MY125555A (en) 2006-08-30
DE69722651T2 (de) 2004-04-08
JP2000507617A (ja) 2000-06-20
DE69722651D1 (en) 2003-07-10
AU713424B2 (en) 1999-12-02
EP0938496B1 (en) 2003-06-04
CN1129606C (zh) 2003-12-03
CA2272990C (en) 2002-11-19
KR20000069045A (ko) 2000-11-25
UA54459C2 (uk) 2003-03-17
IL129519A0 (en) 2000-02-29
SK283800B6 (sk) 2004-02-03
SI20026A (sl) 2000-02-29
SE9604341D0 (sv) 1996-11-26
CZ183299A3 (cs) 2000-05-17

Similar Documents

Publication Publication Date Title
SI20026B (sl) Heptapeptidni analogi - antagonisti oksitocina
RU99113364A (ru) Гептапептидные аналоги окситоцина
AU669856B2 (en) Compositions and methods for the sublingual or buccal administration of therapeutic agents
KR970042553A (ko) 캠프토테신 유도체
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
DE69912952D1 (en) Cyclosporine
SI2068907T1 (en) Pegylated sugars and glycopeptides are associated with glycerol
CN101208091A (zh) 促进口腔吸收的麻醉药的固体药制剂
EP2130548A3 (en) Growth Hormone Releasing Peptides
RU2000100369A (ru) Аналоги пептида лг-рф, их применение и содержащие их фармацевтические композиции
WO2001052894A3 (en) Nasally administrable cyclic peptide compositions
CA2292846A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
JP2005508842A5 (ko)
SI9420001B (sl) Polipeptidni antagonisti bombezina
JP2019523260A5 (ko)
EP1861127A1 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
CA1335622C (en) Bradykinin analogs containing a non-peptide bond
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
JP2006505556A5 (ko)
EP1700608A1 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
AR029930A1 (es) Peptidos analogos de la sustancia p, procesos de sintesis de los mismos, composiciones y el uso de dichos peptidos para la manufactura de un medicamento para el tratamiento de cancer
CN1126999A (zh) 具有催产素拮抗剂活性的肽类化合物
EP0507484A1 (en) A pharmaceutical formulation of aureobasidins
TW386086B (en) Heptapeptide oxytocin analogues

Legal Events

Date Code Title Description
IF Valid on the event date